NEW YORK (GenomeWeb News) — Critical Therapeutics today said Beckman Coulter has exercised a licensing option to continue using its high mobility group box 1 technology.
 
CT said the companies penned a licensing deal in 2005 that gave BC the use of HMGB1 to develop an immunoassay to detect inflammatory diseases. HMGB1 has been identified as a possible mediator of tissue damage caused by inflammation.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.